"Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has recognised Bristol-Myers Squibb's Yervoy (ipilimumab) as a "step change" in the treatment of advanced melanoma, according to draft guidance published on 14 October. Despite this, Yervoy would not be a cost-effective use of NHS resources due to uncertainty over its long-term benefits and, in the absence of a biomarker, the patient populations it could help, says the institute.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.